In the fiercely competitive and risk-laden life sciences industry, what the little-known YM Biosciences (YMI) has achieved in just 12 months caught the attention of a big crowd of investors, analysts, and scientists at the June 3rd meeting of the highly respected American Society for Clinical Oncology (ASCO).